Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 11 | 2022JPM 2022 Day 2: LLY, ABT, AMRN, SNY, AMGN, RHHBY, and TEVAPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 10 | 2022JPM 2022 Day 1: DXCM, NVS, BAYRY, MDT, TDOC, VRTX; Sanofi Partners with BrightInsight; Viking Initiates GLP-1/GIP Dual Agonist Ph1 TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 07 | 2022Senseonics Announces FDA Review for 180-day CGM Nearing Completion; Alnylam and Novartis Announce Collaboration for Liver FailurePurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 06 | 2022Abbott Announces New Category of Biowearables at CES 2022Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 03 | 2022Holiday Hangover: Novo Completes Dicerna Acquisition; FDA Approves Novartis’s Leqvio; Lexicon Submits NDA for Sotagliflozin; CMS Medicare Coverage Expansion Includes Non-adjunctive CGMs; Viatris Beats Sanofi’s Insulin-Pen Patent Invalidation Appeal; Beta Bionics iLet Bionic Pancreas Pivotal Trials UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA Dec 20 | 2021Novo Hosts Wegovy Shortage Call with Investors; Lannett Files Bs-glargine IND; Provention Adds New Management; Intercept NASH Data DelayedPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 17 | 2021Novo Faces New Wegovy Supply ShortagePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 16 | 2021Medtronic Diabetes Receives FDA Warning; Bigfoot Hires New Senior Leaders; Omada’s mHealth Programs Gain Preferred Status on Evernorth Digital Health FormularyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Dec 15 | 2021Lilly Hosts 2021 Investment Community MeetingPurchase Blast
$599
Posted in: Other Dec 14 | 2021Sigilon Announces Strategic Reprioritization; Jaguar Gene Therapy Includes T1DM in Initial Pipeline ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other, SGLT2i Dec 13 | 2021December 13-16 CHMP Agenda; Novo Invests Further in Kalundborg Manufacturing Facilities; CytoDyn Reports Additional Data from Ph2 Leronlimab NASH Trial; Adocia Files Patent for Oral Delivery Technology of PeptidesPurchase Blast
$599
Posted in: Other Dec 10 | 2021Lilly Partners with Regor Therapeutics for Metabolic Drug DiscoveryPurchase Blast
$599
Posted in: Other Dec 09 | 2021Ionis Hosts 2022 Investor Day; Intercept Withdraws OCA MAA in NASHPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Dec 07 | 2021vTv Therapeutics to Reduce Workforce by 65%; Innovent Announces Positive Results for Ph1 GLP-1/GCG from Lilly; Nemaura Completes Initial Shipment of CGM Devices to MySugarWatch DuoPack LimitedPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Dec 06 | 2021Tandem Hosts 2021 R&D Webinar; FDA Accepts IND for G&L's Novel GLP-1 Analogue; BD Announces Name of Diabetes Spin Off CompanyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Dec 03 | 2021Abbott Sues Dexcom Over Breached Settlement Agreement; Bigfoot Clinical Hub Improvements; Hygieia Raises $17M in Series B; ViaCyte’s Ph1/2 VC-02 Preliminary Results Published; Dario Announces New Employer and Provider ContractsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 30 | 2021Sciwind Biosciences Acquires Worldwide Rights to Sanofi's GIP Receptor Agonists; Diamyd Pauses Initiation of Ph3 DIAGNODE-3 Trial; AMF Medical’s Sigi Patch Pump Receives Breakthrough Device Designation; FDA Authorizes Sample Size Expansion for Fractyl Health’s Revitalize-1 Pivotal TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Nov 29 | 2021Libre 2 Android App Cleared in US; CytoDyn Reports Positive Leronlimab NASH Data; Kadimastem Raises $3.2 to Support T1DM Cell Therapy Development; Integrity Applications Changes Name to GlucoTrack, Inc.Purchase Blast
$599
Posted in: Other Nov 24 | 2021Happy Thanksgiving from CVRM! Coming Soon in December...Purchase Blast